Prostate Cancer News and Research

Latest Prostate Cancer News and Research

Study analyzes effect of shift work on prostate cancer

In a recent original article in Deutsches Ärzteblatt International (Dtsch Arztbl Int 112: 463-70), Gael P. Hammer et al. show that shift workers do not develop prostate cancer more frequently than their colleagues who work during the day.

24 Jul 2015

York scientists identify how some micro-RNAs can make prostate cancers resistant to radiotherapy

Scientists at the University of York believe they have identified how some tiny regulatory molecules in cells can make prostate cancers resistant to radiotherapy.

24 Jul 2015

Endocrine Society selects 18 endocrinologists as winners of 2016 Laureate Awards

The Endocrine Society today announced it has chosen 18 accomplished endocrinologists as winners of the organization's prestigious 2016 Laureate Awards.

24 Jul 2015

Mayo Clinic researchers study HDAC inhibitors to find effective treatments for anaplastic thyroid cancer

In their bid to find the best combination of therapies to treat anaplastic thyroid cancer (ATC), researchers on Mayo Clinic's Florida campus demonstrated that all histone deacetylase (HDAC) inhibitors are not created equal.

24 Jul 2015

Gene responsible for cancer growth plays unexpected role in prostate cancer

A gene that is responsible for cancer growth plays a totally unexpected role in prostate cancer. The gene Stat3 is controlled by the immune modulator interleukin 6 and normally supports the growth of cancer cells. The international research team led by Prof. Lukas Kenner from the Medical University of Vienna, the Veterinary University of Vienna, and the Ludwig Boltzmann Institiute for Cancer Research (LBI-CR) discovered a missing link for an essential role of Stat3 and IL-6 signalling in prostate cancer progression.

22 Jul 2015

Study examines link between use of diabetes drug pioglitazone and increased risk of bladder cancer

Although some previous studies have suggested an increased risk of bladder cancer with use of the diabetes drug pioglitazone, analyses that included nearly 200,000 patients found no statistically significant increased risk, however a small increased risk could not be excluded, according to a study in the July 21 issue of JAMA.

22 Jul 2015

New genomic fingerprint may predict prostate cancer risk in African American men

African American men are more likely to develop prostate cancer than European American men, and are also more than twice as likely to die from it. Although there are many reasons that contribute to this health disparity, new research shows that African American men may have a distinctly different type of prostate cancer than European American men, according to new genomic fingerprinting results.

21 Jul 2015

UCLA scientists identify new method to deliver glucose to pancreatic and prostate cancer cells

UCLA scientists have for the first time identified a new sodium-dependent mechanism to deliver glucose—the body's main fuel that drives tumor growth—to pancreatic and prostate cancer cells, offering new hope in the fight against two of the deadliest forms of the disease.

21 Jul 2015

NeoGenomics announces launch of new germline cancer predisposition testing services

NeoGenomics, Inc., a leading provider of cancer-focused genetic testing services, announced today the launch of a new line of germline cancer predisposition testing services. The new tests include comprehensive testing for BRCA1 and BRCA2 encompassing an analysis of all exons and adjacent intronic regions.

20 Jul 2015

Increased radiation dose offers survival benefit for men with medium- and high-risk prostate cancer

Increased radiation dose is associated with higher survival rates in men with medium- and high-risk prostate cancer, but not men with low-risk prostate cancer, according to a new study from Penn Medicine published this week in JAMA Oncology. Already-high survival rates for men with low-risk prostate cancer were unaffected by higher radiation dosages compared to lower radiation dosages.

17 Jul 2015

Novogen's Anisina granted FDA Orphan Drug Designation for neuroblastoma

US-Australian drug discovery company, Novogen Limited, today announced that it has received notification from the U.S. Food and Drug Administration that its chemotherapy candidate drug, Anisina, has been granted Orphan Drug Designation for neuroblastoma.

16 Jul 2015

Accuray announces presentation of CyberKnife System data at AAPM annual meeting

Accuray Incorporated announced today that studies on the clinical use of the CyberKnife System, the only robotic SBRT system capable of tracking and automatically correcting for target motion, continue to demonstrate the benefits of its precise, innovative treatment delivery techniques.

14 Jul 2015

New study evaluates impact of U.S. Preventive Services Task Force Guidelines for PSA screening

Current U.S. Preventive Services Task Force Guidelines for prostate screening may be impacting the detection of high-risk prostate cancer.

14 Jul 2015

Single molecule appears to be central regulator driving cancer metastasis

Cancer is a disease of cell growth, but most tumors only become lethal once they metastasize or spread from their first location to sites throughout the body. For the first time, researchers at Thomas Jefferson University in Philadelphia report a single molecule that appears to be the central regulator driving metastasis in prostate cancer.

14 Jul 2015

Study shows that Anisina has potential to improve effectiveness of chemotherapy in children with cancer

US-Australian drug discovery company, Novogen Limited, today announced details of an in vivo proof of concept study that demonstrates their lead anti-tropomyosin drug candidate, Anisina, has the potential to improve the effectiveness of chemotherapy in children and reduce life-long side-effects.

14 Jul 2015

OncoGenex's custirsen Phase 3 ENSPIRIT trial for treatment of NSCLC patients continues as planned

OncoGenex Pharmaceuticals, Inc. announced today that its Phase 3 ENSPIRIT trial evaluating custirsen in the treatment of advanced or metastatic non-small cell lung cancer (NSCLC) is continuing as planned per the recommendation of an Independent Data Monitoring Committee (IDMC). This decision was based upon completion of the second and final planned interim futility analysis.

13 Jul 2015

NSU cancer researcher selected for prestigious J. William Fulbright award

Nova Southeastern University cancer researcher Appu Rathinavelu, Ph.D., was selected for a prestigious J. William Fulbright award to conduct cancer research and training in India. Dr. Rathinavelu is associate dean for institutional planning and development at NSU's College of Pharmacy and executive director of NSU's Rumbaugh-Goodwin Institute for Cancer Research.

9 Jul 2015

U-M researchers develop first-ever 3D model to help study treatment for pelvic organ prolapse

It's a mysterious condition often linked to childbirth that causes distress and discomfort and requires surgery for more than 200,000 women a year - but there's no good way to study it. Now, researchers at the University of Michigan have developed the first-ever 3D complete computer model to help study treatment for pelvic organ prolapse, a weakening of muscles and ligaments that causes organs like the bladder to drop from their normal place. For many women, the condition causes urinary problems, painful intercourse and uncomfortable pressure.

9 Jul 2015

Study examines recent trends in community-based practices to improve management of localized prostate cancer

After years of overtreatment for patients with low-risk prostate cancer, rates of active surveillance/ watchful waiting increased sharply in 2010 through 2013, and high-risk disease was more often treated appropriately with potentially curative local treatment rather than androgen deprivation alone, according to a study in the July 7 issue of JAMA.

8 Jul 2015

Study: Extended-field IMRT for cervical or endometrial cancer does not increase risk of duodenal toxicity

A study of women with cervical or endometrial cancer who require treatment to the para-aortic (PA) lymph nodes can safely receive extended-field intensity modulated radiation therapy (EF-IMRT) without increased risk of duodenal toxicity, according to a study published in the July-August 2015 issue of Practical Radiation Oncology, the American Society for Radiation Oncology's journal focused on the clinical practice of radiation oncology.

8 Jul 2015

Prostate Cancer News and Research

Latest Prostate Cancer News and Research

Study analyzes effect of shift work on prostate cancer

York scientists identify how some micro-RNAs can make prostate cancers resistant to radiotherapy

Endocrine Society selects 18 endocrinologists as winners of 2016 Laureate Awards

Mayo Clinic researchers study HDAC inhibitors to find effective treatments for anaplastic thyroid cancer

Gene responsible for cancer growth plays unexpected role in prostate cancer

Study examines link between use of diabetes drug pioglitazone and increased risk of bladder cancer

New genomic fingerprint may predict prostate cancer risk in African American men

UCLA scientists identify new method to deliver glucose to pancreatic and prostate cancer cells

NeoGenomics announces launch of new germline cancer predisposition testing services

Increased radiation dose offers survival benefit for men with medium- and high-risk prostate cancer

Novogen's Anisina granted FDA Orphan Drug Designation for neuroblastoma

Accuray announces presentation of CyberKnife System data at AAPM annual meeting

New study evaluates impact of U.S. Preventive Services Task Force Guidelines for PSA screening

Single molecule appears to be central regulator driving cancer metastasis

Study shows that Anisina has potential to improve effectiveness of chemotherapy in children with cancer

OncoGenex's custirsen Phase 3 ENSPIRIT trial for treatment of NSCLC patients continues as planned

NSU cancer researcher selected for prestigious J. William Fulbright award

U-M researchers develop first-ever 3D model to help study treatment for pelvic organ prolapse

Study examines recent trends in community-based practices to improve management of localized prostate cancer

Study: Extended-field IMRT for cervical or endometrial cancer does not increase risk of duodenal toxicity

What to know about prostate cancer eBook

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Prostate Cancer News and Research

Latest Prostate Cancer News and Research

What to know about prostate cancer eBook

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Newsletters you may be interested in